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Design and baseline characteristics of the ParkFit 
study, a randomized controlled trial evaluating 
the effectiveness of a multifaceted behavioral 
program to increase physical activity in Parkinson 
patients
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Abstract
Background: Many patients with Parkinson's disease (PD) lead a sedentary lifestyle. Promotion of physical activities 
may beneficially affect the clinical presentation of PD, and perhaps even modify the course of PD. However, 
because of physical and cognitive impairments, patients with PD require specific support to increase their level of 
physical activity.
Methods: We developed the ParkFit Program: a PD-specific and multifaceted behavioral program to promote 
physical activity. The emphasis is on creating a behavioral change, using a combination of accepted behavioral 
motivation techniques. In addition, we designed a multicentre randomized clinical trial to investigate whether this 
ParkFit Program increases physical activity levels over two years in sedentary PD patients. We intended to include 
700 sedentary patients. Primary endpoint is the time spent on physical activities per week, which will be measured 
every six months using an interview-based 7-day recall.
Results: In total 3453 PD patients were invited to participate. Ultimately, 586 patients - with a mean (SD) age of
64.1 (7.6) years and disease duration of 5.3 (4.5) years - entered the study. Study participants were younger, had a 
shorter disease duration and were less sedentary compared with eligible PD patients not willing to participate. 
Discussion: The ParkFit trial is expected to yield important new evidence about behavioral interventions to 
promote physical activity in sedentary patients with PD. The results of the trial are expected in 2012.
Trial registration: http://clinicaltrials.gov (nr NCT00748488).
Background
Parkinson's disease (PD) is a progressive neurological 
disorder characterized by both motor symptoms (such 
as bradykinesia and postural instability) and non-motor 
symptoms (such as depression and cognitive impair- 
m ent)[1]. Both m otor and non-m otor symptoms can 
result in reduced physical activity[2,3].
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Observations in non-parkinsonian populations suggest 
that participating in regular physical activity has preven­
tive effects (e.g. cardiovascular events, diabetes mellitus, 
dementia)[4-6] and positive symptomatic effects (on 
depression[7], sleep disturbances[8], health-related qual­
ity of life)[9]. Studies in PD patients concluded that 
brief physical therapy interventions can improve flexibil­
ity, balance and muscle strength[10,11]. In addition, pre- 
clinical evidence in animals with experim ental 
parkinsonism raised the possibility that physical activity 
may directly alter the neurodegenerative process[12,13].
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A critical question remains how PD patients can be 
stimulated best to achieve an enduring increase in their 
physical activities in daily life, in order to prevent co- 
morbid complications and to improve symptoms.
Simply informing subjects about the health benefits of 
physical activity is not enough to attain a sustained 
behavioral change. The challenges to induce a lasting 
change in exercise behavior are particularly great for 
neurological patients. To change lifestyle, behavioral 
program s should focus on appropriate supervision, 
social support from spouses and caregivers, and the 
individual's preferences and needs[14-16]. Achieving an 
enduring behavioral change also calls for specific strate­
gies such as goal setting, problem-solving techniques 
and motivational interviewing[14,16,17]. Physical activity 
prom oting program s including such elem ents were 
effective in sedentary people[15], patients with chronic 
heart failure[16], and patients with COPD[18].
Stimulated by these observations, we developed the 
ParkFit program: a multifaceted intervention to promote 
physical activity in sedentary patients with PD. In addi­
tion, we developed the ParkFit trial to investigate 
whether this program affords increased physical activity 
levels that persist for two years. The trial will also search 
for possible health benefits and risks of increased physi­
cal activity. Here, we describe the study design and 
baseline characteristics of this ParkFit trial.
Methods
Study Design
The ParkFit trial is a multicentre, randomized controlled 
trial comparing two arms: physical therapy with specific 
emphasis on promoting a physically active lifestyle (Park­
Fit Program); and matched physical therapy with specific 
emphasis on safety and quality of performing daily activ­
ities (ParkSafe Program) (Figure 1). Trial duration is two 
years. Full ethical approval has been granted for the 
study (CMO Regio Arnhem-Nijmegen). The study is 
registered at clinicaltrials.gov (nr NCT00748488).
Patients
We started with all patients who visited their neurolo­
gist in 2007, 2008 or 2009 in 32 participating commu­
nity hospitals. Eligibility criteria were: (a) PD, according 
to the UK Brain Bank Criteria[19]; (b) age between 40 
and 75 years; (c) sedentary lifestyle defined as: < 3 times 
a week vigorous-intensity physical activity for < 60 min­
utes; or < 3 times a week moderate-intensity physical 
activity for < 150 minutes);[20] (d) Hoehn and Yahr < 3. 
Exclusion criteria were: (a) unclear diagnosis (no gratify­
ing and sustained response to dopaminergic therapy); 
(b) MMSE < 24); (c) unable to complete Dutch ques­
tionnaires; (d) severe co-morbidity interfering with daily 
functioning; (e) daily institutionalized care; and (f) deep
brain surgery. Informed consent was obtained before the 
first assessment.
The Intervention
After baseline assessment, patients were randomly 
assigned to the ParkFit or ParkSafe Program. In both 
groups, patients receive high quality physical therapy: 
both interventions are delivered exclusively by experi­
enced therapists who participate in the Dutch Parkin- 
sonN et[21,22]. Patients in both treatm ent arms are 
offered an equal maximum number of treatm ent ses­
sions (i.e. 35 sessions of 30 minutes a year; Table 1). 
Therapists contact patients at least every six months to 
investigate if there are new aims.
ParkFit Program
Widely used behavioral change techniques, with demon­
strated effectiveness[16,18] and based on models of 
behavioral change[14,17], are combined in the ParkFit 
Program to stimulate patients to increase their physical 
activity levels.
1) Brochure ParkFit Patients receive a brochure cover­
ing specific strategies to promote a behavioral change. 
These strategies include: education about the benefits of 
physical activity, advice about suitable activities, identify­
ing and overcoming any perceived barriers to engage in 
physical activity, setting goals, and recruiting social sup- 
port[14,23,24]. Part of the educational workbook is a 
health contract: a w ritten agreem ent signed by the 
patient and physiotherapist to support them in initiating 
and maintaining physical activities[25]. A logbook moni­
tors the specific goals.
2) Personal Activity Coach Physical therapists serve as 
personal activity coaches who guide patients towards a
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Table 1 The ParkFit and the ParkSafe program
ParkFit ParkSafe
Intensity Maximum of 19 physicaltherapy sessions based on problems and Maximum of 35 physicaltherapy sessions based on problems
Year 1 disabilities as perceived by each individualpatient; the systematic and
way of disabilities as perceived by each individualpatient; the
tailoring goals is described in the evidence-based guideline for systematic way
p h y s i c a l o f  tailoring goals is described in the evidence-based 
therapy in PD guideline
for physicaltherapy in PD
Intensity 
Year 2
Specific
Elements
16 coaching sessions to identify and focus on individualbeliefs 
and aims to
promote a physically active lifestyle
Maximum of 23 physicaltherapy sessions based on problems and 
disabilities as perceived by each individualpatient
12 coaching sessions to identify and focus on individualbeliefs 
and aims to
promote a physically active lifestyle 
ParkFit Brochure:
• Education about benefits of physical therapy
• Identifying aims of physical therapy
• Education about the benefits of physical activity
• Identifying barriers to engage physical activity
• Setting goals
• Recruiting social support
• Sign a health contract to support patients in initiating and 
maintaining
physical activities
• A logbook to describe and monitor the specific goals
Maximum of 35 physicaltherapy sessions based on problems 
and
disabilities as perceived by each individualpatient
ParkSafe Brochure:
• Education about benefits of physical therapy
• Identifying aims of physical therapy
• Education about the importance of safety when performing 
daily activities
Physicaltherapist:
who treat the patient in order to obtain the aims of
the individualprojected treatment plan
PersonalActivity Coach:
who guide patients towards a more active
lifestyle
Goalsetting: creating goals to increase the level 
of physicalactivity in order to obtain the half- 
year-goals as formulated in the health contract; 
goals w illbe  evaluated as w ellas experienced 
barriers and possible solving techniques
Ambulatory Activity Monitor: gives visual 
feedback about the leve lo f physicalactivity 
during the day
Bi-annualnewsletter: specific information about 
physicalactivity, generalinformation about 
Parkinson's disease, and generalentertainment in 
order to facilitate compliance
Physicaltherapist:
who treat the patient in order to obtain the aims of 
the individualprojected treatment plan
Bi-annualnewsletter: specific information about 
physicaltherapy, generalinformation about 
Parkinson's disease, and generalentertainment in 
order to facilitate compliance
more active lifestyle, during specific coaching sessions. 
Their task is to educate patients about the beneficial 
effects of physical activity. Patients are additionally sti­
mulated to participate in group exercise to experience 
the beneficial effects of physical activity and to receive 
social support from fellow patients[26]. For safety rea­
sons, all patients are encouraged to receive a preventive 
sports medical screening.
3) Goal setting  Patient and coach create activity goals 
in order to obtain the 6-month-goals (as formulated in 
the health contract). Goals have to be realistic, concrete
and individualized and have to be formulated in a sys­
tematic way, based on behavioral change theories[25].
4) Ambulatory Activity M onitor with visual feedback 
Patients receive a personal ambulatory m onitor with 
automated visual feedback showing the amount of actu­
ally delivered daily physical activity, recorded by a triax­
ial accelerometer[27,28]. Additionally, a personalized 
website shows the activity history[27]. Previous work 
showed that feedback from pedometers increases physi­
cal activity levels in COPD patients[29], sedentary work- 
ers[30] and patients with diabetes mellitus[31].
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5) Physical therapy The ParkFit Program also includes 
a maximum of 19 physical therapy sessions in year 1 
and 23 in year 2. Based on individual disabilities, thera­
pist and patient jointly formulate treatment aims based 
on the evidence-based guideline of physical therapy for 
PD[32].
ParkSafe Program
The ParkSafe Program includes physical therapy inter­
ventions from the physical therapy guideline for PD[32] 
to stim ulate patients to move more safely, e.g. by 
improving the quality of transfers, but without explicit 
emphasis on reaching a physically active lifestyle.
1) Brochure ParkSafe Patients receive a brochure with 
information about the benefits of physical therapy[32]. 
Specific emphasis is given to the importance of safety 
when performing daily activities.
2) Physical therapy Patients receive an individualized 
physical therapy program. We maximized the total 
number of sessions at 35/year, to avoid large differences 
in number of treatment sessions between the two arms 
(patients in the ParkFit arm also receive 35 annual ses­
sions: 19 physiotherapy plus 16 coach sessions). 35 ses­
sions is considered sufficient for patients in Hoehn and 
Yahr stage < 3. Physical therapist and patient jointly for­
mulate the aims of the projected treatment plan, based 
on individual problems and disabilities. The aims of the 
physical therapy sessions in both treatm ent arms are 
derived from the guideline for physical therapy in PD.
Implementation
Training for physical therapists
All participating physical therapists were specifically 
trained to treat patients in both treatm ent arms and 
informed about the aim of the study. Special attention 
was given to models of behavioral change, [14,17] to spe­
cific strategies of coaching sedentary patients,[15,33] and 
to the technique of setting realistic, concrete and indivi­
dualized goals[25]. Throughout the trial, therapists con­
tinuously register the individual treatment sessions.
Outcome measures 
Baseline characteristics
Blood pressure, height, body weight, education and 
employment are assessed at baseline as well as alcohol 
use, smoking history and lifetime physical activity[34]. 
Participants in the ParkFit Program also completed a 
questionnaire about attitude, social support and self-effi­
cacy towards physical activity.
Primary endpoint: level o f physical activity 
Primary endpoint is the level of physical activity, as 
measured with a 7-day recall, based on an interview- 
based physical activity questionnaire, the LAPAQ[35]. 
Patients are asked to list their daily amount of activity 
(frequency and duration), so total time spent on physical
activity (in hours per day) will be calculated. A MET- 
value will be used to calculate the number of kilocal­
ories spent per day per kilogram of body weight[36]. 
The LAPAQ is completed during a face-to-face inter­
view (at baseline, 12 and 24 months) and at additional 
time points by telephone (6 and 18 months). We assume 
that patients will increase their level of physical activity 
during the first months of intervention and then main­
tain this level. Therefore, main endpoint is the level of 
physical activity during the entire follow-up period (i.e. 
the mean of 6, 12, 18 and 24 months).
Secondary endpoints (Table 2)
Secondary measures include: (a) physical fitness, mea­
sured with the six minute walk test (6MWT)[37]; (b) 
quality of life, measured with the PDQ-39[38]; and (c) 
level of physical activity in time and kilocalories per 
week, measured with the same tri-axial accelerometer 
that is used as feedback-tool in the ParkFit Program[28]. 
The level of physical activity is additionally measured 
with a physical activity diary.
Additional measures
Patients who increased their amount of physical activity 
will be compared with patients unable to achieve this, 
to assess specific health consequences. Disease progres­
sion (UPDRS motor section [39]; 9-hole peg board test 
[40]), mobility (Timed Up and Go test[41]), quality of 
sleep (SCOPA-sleep[42]), anxiety and depression 
(HADS[43]), fatigue (Fatigue Severity Scale[44]), and 
cognitive functioning (Table 2 for test battery) are 
assessed. Additionally, physical fitness is measured with 
the Astrand-Ryhming test[45]. Bone mineral density 
(dual energy X-ray absorptiometry, DXA) is determined 
in a subgroup of 300 patients. PD medication and medi­
cal costs (combined with the EQ-5D[46]) are assessed, 
as well as the number of falls (as an index of safety). 
Patients are asked whether their falls occurred during 
exercise and about the consequences of falls (e.g. 
injuries). Inform ation about other adverse events is 
collected systematically at each physical assessment. 
Blinding
To avoid bias due to more positive expectations of 
patients towards the outcomes of the ParkFit Program, 
patients were initially informed about the fact that there 
are two intervention groups, each with a beneficial inter­
vention. To ensure blinding during assessments, patients 
are assessed by trained assessors who are unaware of 
group allocation. Patients are explicitly asked to not 
share their experiences with the program during the 
assessments.
Sample size calculation
Based on the following power considerations, we aimed 
to include a total of 700 patients. In a small observa­
tional study on physical activity in PD, patients scored 
45% less on the LAPAQ com pared to controls
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Table 2 An overview of patient assessments
Baseline
Visit & 
Questionnaires
6 months
Questionnaires
12 months
Visit & 
Questionnaires
18 m onths
Questionnaires
24 months
Visit & 
Questionnaires
Physical Activity
LAPAQ x x x x x
Activity Monitor x x x x x
Activity Diary x x x x x
Physical Fitness
6 MWT x x x
Astrand-Ryhming test x x x
Quality o f Life
PDQ-39 x x x x x
H ealth  Effects
UPDRS III, motor function x x x
Nine hole peg board test x x x
Timed up and go test x x x
DXA x
SCOPA-sleep x x x x x
HADS x x x x x
FSS x x x x x
Cognitive testing battery* x x x
PD medication x x x x x
Medical costs & EQ-5D x x x x x
Number of falls (monthly) x x x x x
D eterm inants
Blood pressure x x x
Height x x x
Body weight x x x
Education x
Employment x
Alcohol use x x x
Smoking x x x
Lifetime physical activity x
Attitude, SS & SE** x
* Including tests for spatial working memory[49], intra- and extra-dimensional shift performance[50,51], paired associate learning performance[50], phonemic and 
semantic word fluency[52], and complex figure drawing[53]
** Only patients in the ParkFit Program
(unpublished data). The coefficient of variation was 
110%. Based on a difference of 15% (with coefficient of 
variation of 110%) between both treatm ent arms, the 
study will have at least 80% power (when the correlation 
between baseline and follow-up measurements is at least 
0.50 and when the correlation between the various fol­
low-up measurements is at most 0.85). This is also the 
power when the correlations are at least 0.60 and at 
most 0.95, respectively. The power is based on two­
sided 95% confidence intervals. We assumed that 
patients would take part in exercise groups with on 
average eight participants and that the corresponding 
ICC would be 0.1. Based on a previous trial of physical 
therapy for PD involving the national ParkinsonNet 
networks[21], we expect a drop-out rate of 10%.
Randomization
A minimization algorithm is used to randomize patients, 
with the factors region, Hoehn & Yahr stage, age, 
gender and current level of physical activity.
Statistical analyses
All participants who really started with their program, 
will be included in the primary analysis. The results 
after 6, 12, 18 and 24 months will be evaluated using a 
linear mixed model with random nested factors 'patient' 
and 'exercise group'. Fixed factors will be treatm ent 
arm, LAPAQ score at baseline, month, month*treatment 
(interaction), and the factors region, H&Y stage, age, 
gender and bone density assessment. In an additional 
analysis, the influence of H&Y stage, age, gender and 
level of previous sports activities on the success of the
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treatment will be evaluated by including the interaction 
terms between treatment and each of these variables in 
the model. Multiple imputation analyses will be used to 
evaluate the impact of missing values on the outcome. 
Throughout, 95% confidence intervals will be calculated.
Results
Inclusion procedure
Selection of patients ran from September 2008 to Janu­
ary 2010. A total number of 4479 patients received a 
screening questionnaire; 587 (13.1%) did not respond, 
439 (9.8%) were excluded because there was doubt 
about the diagnosis (Figure 2). After invitation for parti­
cipation, 1766 patients were excluded based on our 
exclusion criteria, and 1101 eligible patients were
Patients received 
screening questionnaire
n=4479
Non response n=587
Patients returned 
screening questionnaire
n=3892
No Parkinson’s disease* n=439
Patients with PD 
invited to participate
n=3453
E xcluded based on exclusion criteria n=1766
No sedentary lifestyle** (n=I263) 
Severe disease*** (n=464) 
Not reached by phone (n-30) 
Did not speak Dutch (n=9)
Eligible patients
n=1687
Not willing to participate n = l!0 1
Patients randomized
n=586
ParkFit
n=299
ParkSafe
n=287
F igure  2 Flow  chart o f the inclusion procedure. * No Parkinson's 
disease = patient is diagnosed with parkinsonism or patient declared 
to have no gratifying and sustained response to dopaminergic therapy;
** No sedentary lifestyle = > 3 times a week vigorous-intensity physical
activity > 60 minutes; or > 3 times a week moderate-intensity physical 
activity > 150 minutes; *** Severe disease = H&Y > III; MMSE < 24; 
severe co-morbidity interfering with daily functioning; use of daily care 
in an institution; or deep brain stimulation.
excluded because they were not willing to participate. 
Finally, 586 patients signed informed consent. The num­
ber of enrolled patients is less than the power calcula­
tion required. However, the power remains over 80% 
because only 60% of patients participates in exercise 
groups with an average group size of only three, whereas 
our power calculation assumed that all patients would 
participate in exercise in groups of eight patients.
Baseline characteristics
The most relevant baseline characteristics of included 
patients are presented in Table 3 and compared with 
the characteristics of the complete cohort of PD patients 
and the cohort of patients who were eligible but not 
willing to participate. Study participants were younger, 
had a shorter disease duration and were less sedentary 
com pared with eligible patients not willing to 
participate.
Discussion
Several lines of evidence suggest that regular participa­
tion in physical activity could be important for patients 
with PD[47]. The ParkFit trial was designed to evaluate 
a multifaceted program to achieve an enduring increase 
in physical activity in PD patients. The intervention is 
based on accepted motivational and behavioral change 
models[14,16,17], which will now be employed for the 
first time in PD.
We carefully m onitored the characteristics of all 
invited patients as well as eligible patients who were not 
willing to participate. The results dem onstrate that 
among all PD patients who were invited, 64% indeed 
had a sedentary lifestyle. The results further demon­
strate that eligible PD patients not willing to participate 
were on average somewhat more sedentary in compari­
son with the participants of the study. Should our study 
shows a beneficial effect of the ParkFit behavioral 
change program, efforts must be made to also reach out 
to this subgroup of sedentary patients.
A critical issue in rehabilitation studies is the choice 
for an appropriate control condition, and we have 
selected a program that emphasized safety of movement 
(according to evidence-based guidelines[32]), rather than 
the quantity of movements. Both intervention programs 
are matched for intensity, and are delivered by the same 
therapists. We have taken several measures to avoid bias 
between both treatm ent arms, rendering both groups 
comparable except for the focus on physical activities. 
Because the same therapists participate in both pro­
grams, differences in their personalities should not differ 
between the two treatment arms. A possible drawback is 
contamination. Furthermore, personal preference for a 
specific program  can possibly introduce variation 
between therapists. We strive to avoid this by: (1)
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Table 3 Characteristics of the invited and included patients
Com plete cohort 
of PD  patients
N 3453
Gender (%  male) 59.0
Age (years) 66.1 (7.2)
D isease duration (years) 6.2 (5.7)
Ability to  w a lk  (%)
Normal 814 (23.7)
Slow but independently 1747 (50.8)
Independently with walking aid 605 (17.6)
With help of someone 112 (3.3)
Wheelchair bounded 158 (4.6)
Level o f physical activity (min/week) 144.8 (196.7)
specific training, informing all therapists about the aim 
of the study and the do's and don'ts in both treatment 
arms. They have signed a contract and agreed to keep 
both programs separate. (2) The tools used in ParkFit 
are not freely available. Since all patients receive their 
own Activity Monitor and brochure, therapists cannot 
give these tools to patients allocated to ParkSafe. (3) 
During the trial, therapists are being visited and 
observed during one or more sessions. A standardized 
checklist of prescribed interventions will be completed 
to investigate if contamination is at play. (4) Each thera­
pist will be interviewed, between 3 to 6 months after 
start of the program. The aim is to investigate how 
therapists put the program  into practice, and to re­
emphasize the do's and don'ts of both programs. (5) 
About every two months, the research team contacts 
each therapist to ask them about their individual aims 
in both treatm ent arms. Again, it is emphasized that 
coaching towards a more physically active lifestyle is not 
allowed in ParkSafe. (6) Yearly, a 'booster' session is 
planned for therapists to discuss possible problems and 
to re-emphasize the do's and don'ts.
A strong element of the ParkFit trial is the availability 
of our national ParkinsonNet netw orks[21], which 
allows us to administer the interventions in both treat­
ment arms by therapists with documented experience in 
treating PD patients. The ParkFit trial is one of the lar­
gest and longest lifestyle intervention trials in PD, and is 
the first one to focus on behavioral change as an inter­
mediate to achieve a sustained increase in physical activ­
ity levels.
The endpoints of this trial cover several complemen­
tary domains. A prerequisite is that patients will actually 
increase their physical activity levels. To document this, 
we have selected the time spent on physical activities 
per week as primary endpoint. We choose the LAPAQ 
as primary outcome measure instead of the Activity
Elig ible patients 
Not willing to participate Willing to participate
1101 586
53.4 65.4
67.2 (7.1) 64.1 (7.6)
6.0 (5.6) 5.3 (4.6)
232 (21.3) 157 (26.8)
556 (51.0) 348 (59.4)
302 (27.7) 81 (13.8)
40.1(61.1) 59.2 (71.9)
Monitor because a questionnaire covers a wider range 
of activities[48].
We also want to see whether physical activity affords 
any symptomatic relief of PD. To this end we have 
included a battery of additional endpoints (including 
quality of life) that measure possible health benefits for 
patients. Safety is also an issue, because physical activity 
may theoretically predispose patients to falls. Therefore, 
this will also be documented in this study. Furthermore, 
costs will be recorded, although we have no specific a 
priori reason to expect drastic increases or reductions in 
costs associated with the interventions of this trial.
In conclusion, the ParkFit trial is expected to yield 
im portant new knowledge about behavioral interven­
tions for patients with PD to change their sedentary life­
style. If the ParkFit Program shows good treatm ent 
compliance and beneficial symptomatic effects, future 
trials could identify which components of our multifa­
ceted approach are most effective. In addition, positive 
results may have implications for different neurological 
disorders where beneficial effects of physical activity 
may be expected. The results of the ParkFit trial are 
scheduled for 2012.
Acknowledgements
This research is supported by grants from ZonMw, The Netherlands 
Organization for Health Research and Development (75020012), and the 
MichaelJ Fox Foundation for Parkinson's research. Furthermore, health 
insurer VGZ financially supported the ParkFit study. Professor Bastiaan R. 
Bloem was supported by a NWO VIDIgrant (016.076.352).
We would like to thank the localcoordinators of the participating general 
hospitals:
A Winogrodzka (Academisch Ziekenhuis Maastricht); JCM Zijlmans (Amphia 
Ziekenhuis); GJ Tissingh (Atrium Medisch Centrum); K Keizer (Catharina- 
ziekenhuis); HJMM Lohmann (Deventer Ziekenhuis); R van Koningsveld 
(Elkerliek Ziekenhuis); AJW  Boon (Erasmus Medisch Centrum); E van Wensen 
and FE Strijks (Gelre Ziekenhuizen); GA van Meer (Groene Hart Ziekenhuis); A 
Mosch (HagaZiekenhuis); JP  ter Bruggen (Jeroen Bosch Ziekenhuis); MF 
Roesdi (Kennemer Gasthuis); E Berger ('t Lange Land Ziekenhuis and 
Medisch Centrum Haaglanden); AGGC Korten (Laurentius Ziekenhuis); M 
Westerink (Maasstad Ziekenhuis); M Aramideh (Medisch Centrum Alkmaar); R
van Nimwegen et al. BMC Neurology 2010, 10:70
http://www.biomedcentral.com/1471-2377/10/70
Page 8 of 9
Rundervoort (Medisch Centrum Haaglanden); FA Rooyer (Orbis Medisch 
Centrum); DJ Kamphuis (Reinier de Graaf Groep); GJ de Jong (Sint Franciscus 
Gasthuis); L van Hooff (Franciscus Ziekenhuis); K Lemmen (Slingeland 
Ziekenhuis); ThJM Breuer (St. Anna Ziekenhuis); JM J Krul and PM Laboyrie 
(Tergooiziekenhuizen); FJW Opstelten (VieCuri Medisch Centrum); AMG Sas 
(Vlietland Ziekenhuis); PJ Nederveen (Westfriesgasthuis), J Lion (Ziekenhuis 
Bernhoven); and C Jansen (Ziekenhuis Gelderse Vallei) for their participation 
in the ParkFit study group.
Furthermore, we would like to thank JW  Custers and PJ van der Wees (Royal 
Dutch Society for Physical therapy), SI Detaille and V Peters (Seneca,
Expertise Centre for Sport, Work and Health, HAN University of Applied 
Sciences), MT Hopman (Department of Physiology, Radboud University 
Nijmegen Medical Centre), MWA Jongert (TNO Netherlands Organization for 
Applied Scientific Research), YPT Kamsma (University Medical Center 
Groningen), SHJ Keus (Departments of Physical Therapy and Neurology, 
Leiden University Medical Centre; Department of Neurology, Donders 
Institute for Brain, Cognition and Behavior, Radboud University Nijmegen 
Medical Centre), G Kwakkel (VU University Medical Center), H Leutscher 
(Disability Sports Netherlands), W  Oerlemans (HAN University of Applied 
Sciences), CJM van Santen (Society of Exercise Therapists Cesar and 
Mensendieck), NHMJ van Velthoven (Netherlands Olympic Committee * 
Netherlands Sports Federation), AMJ van de Wert (Netherlands Institute for 
Sport en Physical Activity), and T Wolff (Parkinson Vereniging) for their 
participation in the ParkFit advisory board.
Author details
]Radboud University Nijmegen Medical Centre (RUNMC); Nijmegen Centre 
for Evidence Based Practice (NCEBP), Department of Neurology, Nijmegen, 
The Netherlands. 2RUNMC; Donders Institute for Brain, Cognition and 
Behavior; Department of Neurology, Nijmegen, The Netherlands. 3RUNMC; 
Departments of Rehabilitation and Allied Health Occupations, Nijmegen, The 
Netherlands. 4HAN University of Applied Sciences; Nijmegen, The 
Netherlands. 5RUNMC; Department of Epidemiology, Biostatistics and HTA, 
Nijmegen, The Netherlands. 6University Medical Center Utrecht; Department 
of Rehabilitation, Nursing Science and Sport, Utrecht, The Netherlands. 
7RUNMC; Nijmegen Centre for Evidence Based Practice (NCEBP), Scientific 
Institute for Quality of Healthcare, Nijmegen, The Netherlands.
Authors' contributions
MM, BRB and FJGB wrote the grant application and supervised all project 
staff. MvN, ADS, GFB, FJGB, BRB, MM, and members of the ParkFit study 
group contributed to the research design. MvN, ADS, KS and MM 
participated in organization and execution of the research project. GFB was 
responsible for sample size calculation and statistical analysis. MvN and SO 
wrote first draft of the manuscript. All authors read and approved the final 
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 July 2010 Accepted: 19 August 2010 
Published: 19 August 2010
References
1. Lees AJ, Hardy J, Revesz T: Parkinson's disease. Lancet 2009, 373:2055-2066.
2. Fertl E, Doppelbauer A, Auff E: Physical activity and sports in patients 
suffering from Parkinson's disease in comparison with healthy seniors. J  
Neural Transm Park Dis Dement Sect 1993, 5:157-161.
3. van Nimwegen ML, van Rossum E, Deeg DJ, Bloem BR, Borm GF, van der 
Horst M, et al: The level of physical activity in patients with Parkinson's 
disease. Parkinsonism Relat Disord 2008, 14:67-68.
4. Warburton DE, Nicol CW, Bredin SS: Health benefits of physical activity: 
the evidence. CMAJ 2006, 174:801-809.
5. Mora S, Cook N, Buring JE, Ridker PM, Lee IM: Physical activity and 
reduced risk of cardiovascular events: potential mediating mechanisms. 
Circulation 2007, 1 16:2110-2118.
6. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, et al:
Exercise is associated with reduced risk for incident dementia among 
persons 65 years of age and older. Ann Intern Med 2006, 144:73-81.
7. Blumenthal JA, Babyak MA, Moore KA, Craighead WE, Herman S, Khatri P, 
et al: Effects of exercise training on older patients with major 
depression. Arch Intern Med 1999, 159:2349-2356.
8. Driver HS, Taylor SR: Exercise and sleep. Sleep Med Rev 2000, 4:387-402.
9. Acree LS, Longfors J, Fjeldstad AS, Fjeldstad C, Schank B, Nickel KJ, et al: 
Physical activity is related to quality of life in older adults. Health Qual 
Life Outcomes 2006, 4:37.
10. Crizzle AM, Newhouse IJ: Is physical exercise beneficial for persons with 
Parkinson's disease? Clin J  Sport Med 2006, 16:422-425.
11. Hirsch MA, Farley BG: Exercise and neuroplasticity in persons living with 
Parkinson's disease. Eur J  Phys Rehabil Med 2009, 45:215-229.
12. Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P, et al: 
Effects of treadmill exercise on dopaminergic transmission in the 1- 
methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of 
basal ganglia injury. J  Neurosci 2007, 27:5291-5300.
13. Tillerson JL, Caudle WM, Reveron ME, Miller GW: Exercise induces 
behavioral recovery and attenuates neurochemical deficits in rodent 
models of Parkinson's disease. Neuroscience 2003, 119:899-911.
14. Bandura A: Health promotion by social cognitive means. Health Educ 
Behav 2004, 31:143-164.
15. Hillsdon M, Foster C, Thorogood M: Interventions for promoting physical 
activity. Cochrane Database Syst Rev 2005, CD003180.
16. Brodie DA, Inoue A: Motivational interviewing to promote physical 
activity for people with chronic heart failure. J  Adv Nurs 2005, 50:518-527.
17. Prochaska JO, Velicer WF: The transtheoretical model of health behavior 
change. Am J  Health Promot 1997, 12:38-48.
18. Hospes G, Bossenbroek L, ten Hacken NH, van HP, de Greef MH: 
Enhancement of daily physical activity increases physical fitness of 
outclinic COPD patients: results of an exercise counseling program. 
Patient Educ Couns 2009, 75:274-278.
19. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch 
Neurol 1999, 56:33-39.
20. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al: 
Physical activity and public health in older adults: recommendation 
from the American College of Sports Medicine and the American Heart 
Association. Med Sci Sports Exerc 2007, 39:1435-1445.
21. Munneke M, Nijkrake MJ, Keus SH, Kwakkel G, Berendse HW, Roos RA, et al: 
Efficacy of community-based physiotherapy networks for patients with 
Parkinson's disease: a cluster-randomised trial. Lancet Neurol 2010,
9:46-54.
22. Nijkrake MJ, Keus SH, Overeem S, Oostendorp RA, Vlieland TP, Mulleners W, 
et al: The ParkinsonNet concept: development, implementation and 
initial experience. Mov Disord 2010, 25:823-829.
23. Nied RJ, Franklin B: Promoting and prescribing exercise for the elderly. 
Am Fam Physician 2002, 65:419-426.
24. Schutzer KA, Graves BS: Barriers and motivations to exercise in older 
adults. Prev Med 2004, 39:1056-1061.
25. Haber D, Rhodes D: Health contract with sedentary older adults. 
Gerontologist 2004, 44:827-835.
26. Resnick B, Nigg C: Testing a theoretical model of exercise behavior for 
older adults. Nurs Res 2003, 52:80-88.
27. 2010 [http://www.directlife.philips.com], DirectLife triaxial accelerometer for 
movement registration (TracmorD) (Philips New Wellness Solutions, Lifestyle 
Incubator, the Netherlands).
28. Bonomi AG, Plasqui G, Goris AH, Westerterp KR: Estimation of Free-Living 
Energy Expenditure Using a Novel Activity Monitor Designed to 
Minimize Obtrusiveness. Obesity (Silver Spring) 2010.
29. de Blok BM, de Greef MH, ten Hacken NH, Sprenger SR, Postema K,
Wempe JB: The effects of a lifestyle physical activity counseling program 
with feedback of a pedometer during pulmonary rehabilitation in 
patients with COPD: a pilot study. Patient Educ Couns 2006, 61 :48-55.
30. Chan CB, Ryan DA, Tudor-Locke C: Health benefits of a pedometer-based 
physical activity intervention in sedentary workers. Prev Med 2004, 
39:1215-1222.
31. Araiza P, Hewes H, Gashetewa C, Vella CA, Burge MR: Efficacy of a 
pedometer-based physical activity program on parameters of diabetes 
control in type 2 diabetes mellitus. Metabolism 2006, 55:1382-1387.
32. Keus SH, Bloem BR, Hendriks EJ, Bredero-Cohen AB, Munneke M: Evidence- 
based analysis of physical therapy in Parkinson's disease with 
recommendations for practice and research. Mov Disord 2007, 22:451-460.
van Nimwegen et al. BMC Neurology 2010, 10:70
http://www.biomedcentral.com/1471-2377/10/70
Page 9 of 9
33. de JJ, Lemmink KA, King AC, Huisman M, Stevens M: Twelve-month effects 
of the Groningen active living model (GALM) on physical activity, health 
and fitness outcomes in sedentary and underactive older adults aged 
55-65. Patient Educ Couns 2007, 66:167-176.
34. Friedenreich CM, Courneya KS, Bryant HE: The lifetime total physical 
activity questionnaire: development and reliability. Med Sci Sports Exerc 
1998, 30:266-274.
35. Stel VS, Smit JH, Pluijm SM, Visser M, Deeg DJ, Lips P: Comparison of the 
LASA Physical Activity Questionnaire with a 7-day diary and pedometer. 
J  Clin Epidemiol 2004, 57:252-258.
36. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al: 
Compendium of physical activities: an update of activity codes and MET 
intensities. Med Sci Sports Exerc 2000, 32:S498-S504.
37. Enright PL, McBurnie MA, Bittner V, Tracy RP, McNamara R, Arnold A, et al: 
The 6-min walk test: a quick measure of functional status in elderly 
adults. Chest 2003, 123:387-398.
38. Peto V, Jenkinson C, Fitzpatrick R: Determining minimally important 
differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 
2001, 30:299-302.
39. The Unified Parkinson's Disease Rating Scale (UPDRS): status and 
recommendations. Mov Disord 2003, 18:738-750.
40. Wade DT: Measurement in neurological rehabilitation. Oxford: Oxford 
University Press 1992.
41. Morris S, Morris ME, Iansek R: Reliability of measurements obtained with 
the Timed "Up & Go" test in people with Parkinson disease. Phys Ther 
2001, 81:810-818.
42. Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM: Assessment 
of sleep and sleepiness in Parkinson disease. Sleep 2003, 26:1049-1054.
43. Mondolo F, Jahanshahi M, Grana A, Biasutti E, Cacciatori E, Di BP: The 
validity of the hospital anxiety and depression scale and the geriatric 
depression scale in Parkinson's disease. Behav Neurol 2006, 17:109-115.
44. Grace J, Mendelsohn A, Friedman JH: A comparison of fatigue measures 
in Parkinson's disease. Parkinsonism Relat Disord 2007, 13:443-445.
45. Siconolfi SF, Cullinane EM, Carleton RA, Thompson PD: Assessing VO2max 
in epidemiologic studies: modification of the Astrand-Rhyming test. Med 
Sci Sports Exerc 1982, 14:335-338.
46. EuroQol-a new facility for the measurement of health-related quality of 
life. The EuroQol Group. Health Policy 1990, 16:199-208.
47. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL: The 
effectiveness of exercise interventions for people with Parkinson's 
disease: a systematic review and meta-analysis. Mov Disord 2008, 
23:631-640.
48. Welk GJ: Physical Activity Assessments for Health-Related Research.
Human Kinetics Publishers Inc 2002.
49. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW: Planning and 
spatial working memory following frontal lobe lesions in man. 
Neuropsychologia 1990, 28:1021-1034.
50. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, et al: 
Fronto-striatal cognitive deficits at different stages of Parkinson's 
disease. Brain 1992, 115(Pt 6):1727-1751.
51. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW: 
Impaired extra-dimensional shift performance in medicated and 
unmedicated Parkinson's disease: evidence for a specific attentional 
dysfunction. Neuropsychologia 1989, 27:1329-1343.
52. Schmand B, Groenink SC, van den DM: [Letter fluency: psychometric 
properties and Dutch normative data]. Tijdschr Gerontol Geriatr 2008, 
39:64-76.
53. Rey A: Psychological examination of traumatic encephalopathy 
[originally published in Archives de Psychologie 1941;28: 286-340; 
Translated by Corwin J, Bylsma F.]. Clin Neuropsychol 1993, 7:4-9.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/10/70/prepub
doi:10.1186/1471-2377-10-70
Cite this article as: van Nimwegen et al.: Design and baseline 
characteristics of the ParkFit study, a randomized controlled trial 
evaluating the effectiveness of a multifaceted behavioral program to 
increase physical activity in Parkinson patients. BMC Neurology 2010 
10:70.
Submit your next manuscript to BioMed Central 
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at fpntral
www.biomedcentral.com/submit v-emidi
